Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Morning, everybody. It's John here. And welcome to our Q4 results. It's another good quarter for us. We've made some good progress. We've got continuing strong performance, double-digit growth again. And we're seeing margin expansion, which is really, really pleasing. The performance remains strong. We're seeing that with good demand across all of our markets and particularly from our Fee-For-Service segment; margins are improving, and good cost control is in place. So we're well positioned. We've predicted a bit of softness in some of our lines in the previous quarter, and we have seen that and we said that it would continue for a little bit longer. But we do see the beginnings of signs of recovery, certainly in Q4. So, we're watching this space as we go through to Q1, as we have continued organic growth and profitability improvements in Healthcare Services, particularly driven by our Sports and Wellness business and our Ambulatory business, while our Diagnostic Services team has continued its momentum. They've got double-digit growth in all of the Fee-For-Service markets and really strong test volume growth. So, well done to the team there. It's really great to see. We predicted that our leverage would come down. And we see that happening. So down at 3.1, and the board has recommended a dividend increase, which I think really reflects our progress. On the right-hand side, you can see organic growth of 10.6%, which is really solid. We see continuing operating leverage coming through and our adjusted EBITA up 20.9%. So again, an encouraging trend for us in the fourth quarter. In terms of margin improvement, you can see that that's followed through as well with a really decent margin increase. Operating cash flow very pleasing indeed, up 56%. So that's very good for us. And a good quarter from that respect, if we move on and look at it from a different perspective in terms of our growth, we've got, as I said before, continued double-digit growth coming through the business again, just to remind everybody, this is despite the fact that we've exited Hungary. So, when we take the Hungary figures into consideration, it decreases even further revenue by country. There's a bit of a change in some of the numbers here. But Poland is strong. Germany reflects the reform change that we're going through that we're still navigating well. Romania shows a decent return for us, and India. From a Euro perspective, they're seen as zero, but from a local currency perspective, the results are different. Currency perspective is up 15%, which is kind of in line with some of the comments that we made in the previous quarter. And we're seeing some good momentum, which we'll talk about later. From a payer perspective, it's relatively stable. If you look at Healthcare Services, it achieved good revenue growth, with 8.5% from an organic perspective, and overall growth reaching 11%. A good percentage of that came from price, which reflects our position of having not shied away from leveraging our proposition to ensure we get the right price for delivering the right services. So the team have done well there. India revenue increased by 14.7% in local currency. And remember, this is despite the fact that we had the strike in one of our main states in October. And our momentum, which I think is the most important word for us when it comes to India, is increasing. And I've always said that this is the business end of our journey in India when it comes to IPO. And we need to get our figures into the right kind of order. And it's pleasing to see that the kind of doctor recruitment that we've done is now starting to see the first signs of maturity. Sports and wellness, key contributor to the Fee-For-Service growth as well as the EBITDA margin improvement. So, that space has been very, very successful. If you look at our membership, our membership growth is relatively small. But of course, we've taken out one of our key countries, Hungary, in that journey. And we have to balance this with how our business has moved over time. We're a much bigger fee-for-service business nowadays, and that's one of the reasons that we took the decision to share with you the customer relationship number within Healthcare Services. And as you can see, Q3, when we gave it to you the first time, was 3.6 million, and we're now up to 3.8 million. Growth on the right-hand side is good. You can see the revenue mix by country is again pretty stable. And from a margin perspective, we've got very strong margin improvement in Healthcare Services going from 15 to 17. So, really pleasing progress from the team. If we look at Diagnostic Services, the momentum continues. So congratulations to everybody in diagnostics. Revenue increased by 13.5%, with organic growth at 9.3%. And price was a smaller part of the increase here. Remember that a big part of our business in diagnostics is in Germany. And the regulations on price in Germany were affected by the reform. We've got double-digit growth in all of our Fee-For-Service markets, and that's been further supported by some public pay, particularly in Ukraine, who have had an incredible year and an incredible work considering the conditions that they operate in. So a big thank you to our team in Ukraine. Based upon the fact that they're doing a fantastic job despite the circumstances, in Germany, we're again seeing signs of private pay growth starting to move up as a consequence of the public funding changes. But overall, if we look at all of 2025 and consider the reform that happened in Germany, we've really navigated that position well. And we mentioned earlier that we've seen strong test increases, up by 17.6%, which is a really good result for the team. So if we go across, we've got good growth in revenue, we've got a relatively stable revenue by country, but some really good increases in different lines. We still have margin increase in Diagnostic Services as well, 17.3% from 16.1%, which again is really pleasing. And here you can see the lab tests are starting to move up. And that will be strong. Some of this momentum, of course, is caused by Copernicus, the SIM lab acquisition, which is starting to show through in our numbers, and, as expressed before, we're fully on track now with our activities in that area. If we go and have a quick look at 2025, I think 2025 was a very strong year for us. We've made significant progress as a team. We've got organic growth at 12.7%, our overall revenues growing 13.7%, which is truly excellent. We've made excellent progress from an EBITDA perspective, good progress from a margin perspective, very good cash flow, and a positive impact from a dividend perspective. So we've got a really strong track record in terms of stating the direction that we'll take over a three-year period and looking to make sure that we outperform what we say. And if you remember back three years ago when we first went through these numbers, it was seen as quite a challenging position for us. We've navigated the German reform really well in 2025. I think we've got another quarter to go before we see the full effects. The acquisitions we've done have been embedded very, very well. And as a consequence of that progress, you can see that our return on invested capital is increased quite nicely and getting into a more appropriate zone. So we're really pleased with that. And then if you look at the 2023-2025 targets, we're in a very lucky position, a very privileged position. A lot of hard work has gone in to be able to deliver this. But from a revenue perspective, tick; from an EBITDA perspective, tick; from a leverage perspective, tick. And from a dividend policy perspective, tick. And then even if we look at our alternative measures, we've got a couple of ticks in the boxes there. So it's nice to see so many things being ticked off and being achieved. But this is all history now. It's all part of our past. It's not part of our future. And we'll move on as we go through today and tomorrow. To tell you much more about how we intend to improve on this over future years. Now I'll hand over to Anand, who will talk you through more of the financial details of the quarter, and I'll come on at the end, and then we'll answer the questions. Thank you, John, and good morning, everyone. So, as John said, another solid quarter for Medicover ending FY 25. So, from a revenue perspective, we achieved 611 million, representing double-digit growth in total revenue on a total basis, along with strong organic growth year-on-year, as previously mentioned; furthermore, in terms of profit measures, there was good year-on-year growth, particularly in margin, leading to strong EBITDA. And the EBIT lines were growing faster than our revenues. So if you look at EBIT, for example, in the quarter, EBIT of 35.2 million, strong growth with a margin of 5.7%, which is 150 basis points year on year. Also, another thing to note is net profit of 17.3 million at a margin of 2.8%. So strong flow through of our revenues into the quarter. And the final profit metric I'll talk about is the EBITDAaL number, because obviously leases are a part of our cost base and how we grow our business. So EBITDA of 57 million, up 30%, with margin rate up 140 basis points year on year, at 9.3%. So I would say a solid quarter. And in line with the messaging that John and I gave at the end of Q3. And if you look across the business units, it's again, similar messages of growth that we saw in prior quarters, but not as pronounced year on year, I would say. So looking at Healthcare first, organic revenue was up 11%, with price driving 6% and volume driving 5%. EBITDA was 72.5 million, a growth of 23%. And John's already mentioned that we had margin expansion of 200 basis points in the quarter. So really pleasing. I guess I'll touch on the EBITDA loss on the immature hospitals. So year on year, the loss is slightly less, moving from 3.3 to 3.1; quarter on quarter, though, as we opened a new hospital operationally. Then the loss increased from 2.7 million to 3.1 million in the quarter. So I would summarize that as a good quarter for healthcare and doing what we said we would do in terms of diagnostics. John's already said it was a really strong performance by the team. Well done to them. So organic growth of about 10% with price driving 3% and volume driving 7%. We talk about Germany a lot, and I think that even in Germany, despite the reduction in prices, we are still getting strong volume growth in that market from an EBITDA perspective. 33.3 million, growing 120 basis points year on year to 17.3%. And John's mentioned a good move in terms of the FFS markets and a positive performance in Germany, from a payer mix perspective. So in summary, a strong quarter to end the year in diagnostics too. So if I wrap up the full year, I guess I would say a stellar year in terms of consistent growth across both business units, with double-digit revenue growth and profit measures growing faster than revenue, resulting in improvement in margins. The other thing I'd add is actually a really strong performance in cash, and a step-up in return on investment metrics, to highlight a couple of measures. So revenue just under 2.4 billion, growing 13.7%; EBIT more than doubling to 155.7 million at a margin rate of 6.5%, which is up 310 basis points year on year; and EBITDAaL was $243.1 million, growing 40%, or 190 basis points year on year. All the above are leading to a really strong EPS, so our EPS was €51.4 cents, up from €11.2 cents last year. And as John's already mentioned, we beat the externally guided targets that we gave you for FY 25 across all measures. On this slide, you can see some of the other metrics. From a leverage perspective. John talked about it already in terms of 3.1 down from 3.4 last year and a reduction quarter on quarter as well. So a good result, effective tax rate at 26.1% in line with what we had shared previously. And I would pull out a really strong performance in cash on the quarter and the full year. So our net operating cash of 100 million is up 56% year on year. And on a full year basis, it was 343.7 million, which is up 31% year on year. And if you look at free cash flow, you can see that in the quarter it was 8.4% of our revenue. So a really big step up compared to prior year. The other thing I'd say on that slide is actually a really strong improvement in ROIC. So you'll have seen that we started the year at 6.7% at the end of FY 24, and we've nearly doubled it to 13%. So this really gives comfort that as we expand our margin and invest in white space opportunities, the profit flow-through is flowing through and impacting our investment metrics. On the next slide, you can see where we are on CapEx. So CapEx in the quarter was just under 57 million. There was a bit of catch-up in CapEx from prior quarters as a percentage of revenues. But from a full year perspective, we're about 6.7% of revenues, which is in line with what we've shared previously. And as you can see from the chart on the left, there continues to be clear white space between our free cash flow and our investment growth CapEx. So, a good sign, and we expect that to continue in the future, as the spend in the quarter was, as expected, predominantly in Healthcare Services, a common theme this year. And in terms of growth and maintenance split: roughly 72% was growth, 28% was maintenance. And that's broadly the same split for the full year as well. And finally, in terms of new medical space. So in the year, we added on 77,000m², we ended up 986,000m² at the end of the financial year. Undoubtedly, we'll break past the million in Q1. So in summary, a good quarter to end the year in totality, a strong year in FY 25. And as John mentioned previously, a year in which we beat the targets that we set externally. So now looking forward. And please bear in mind, most of the talking we expect about the future in terms of our numbers and how we get there is expected to be tomorrow. Today is meant to be predominantly about the final quarter. And answering any questions you have on FY25, the future targets are as follows: in a similar vein, these are three-year targets which take us to the period of 2028. So to summarize, we expect organic revenues to be in excess of 3.25 billion. We expect adjusted organic EBITDA to be in excess of 600 million, leverage to be at or under three, which is lower than the previous measures we were given at 3.5, and dividends to be 50% of net profit. And on an illustrative basis, to help you with your models, you can see we expect EBIT to be in excess of 290 million. So you can calculate the EBIT from that based on where we are at the moment. So EBIT growth and adjusted EBITDA to be in excess of 430 million. So you can see the targets that we've got. I think they are ambitious but challenging, and they reflect the strength of our business and the opportunity that we see ahead of us. And with that, I'll come back to John. Today is meant to be predominantly about the final quarter. And, so in terms of key takeaways, 2025 was a strong year; we've successfully achieved our three-year financial targets, which is very positive for us. We've got good organic growth and very significant improved margins from both divisions and a really strong Fee-For-Service (FFS) line, which is a good revenue stream for us. There is room for us to improve. We can, we know that, we see that. And that's really reflected in our future targets. And we believe we can improve from a growth perspective, and we believe we can certainly improve from a margin perspective. We're in very strong markets where we have the opportunity to grow the network that we currently have. We can certainly develop some new products and some new areas of interest for our customers. And, let's not forget that over a long period of time, we put a lot of investment into our business and increased our square meters for quite a period, and we've still got capacity utilization to come. So looking ahead, we're entering a new phase, a phase where we enter it from a position of strength. We're very excited and we're looking forward to it. And so we're in a good place. And just really to end with a big thank you to all the people in Medicover who have committed a lot to achieve the numbers that we committed to three years ago. And who will continue to commit a lot to ensure we achieve them again in three years' time. We expect adjusted organic EBITDA to be in excess of 600 million, leverage to be at or under three, which is lower than the previous target of three and a half; dividends to be 50% of net profit.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Philip Ekengren from ABG. Please go ahead.
Good morning guys. So I'll stay away from asking about the new targets and keep that for tomorrow. But just on margin. So adjusted EBITDA margins up 200 basis points year over year. Could you give us sort of the key drivers behind that increase. And perhaps also if you can split up how much is operational leverage and how much is price. So that increase, please.
From a price perspective, you can see it in the numbers that we've just published; if you go through not only the quarter but for the year, you'll see that from a Healthcare Services perspective, the price component is much stronger. And obviously from a diagnostic services perspective, it's a lot weaker. The increased volume of tests from a diagnostic perspective, as we all know with the diagnostic business, means that once you put more tests through the lines you've already got, it's quite a sweet position for you. So, if the team continues to drive that extra volume, that extra volume will result in operational leverage. And it's pretty similar in Healthcare Services, but not to the same extent of the margin increase. You've got to do a bit more volume from a Healthcare Services perspective to get the same kind of outcome in the financial numbers. But, capacity in Healthcare Services, that's where most of our square meters have been utilized. You've got a bit of mix in there as well. Q4 was a slightly strange quarter, with the holiday pattern as well. That happened over Christmas, which was quite unusual. Lots of different factors in there, but certainly price, certainly capacity, certainly a bit of volume. The usual levers that have an impact on the model make sense.
And on India, it's continuing to show some double-digit growth in local currency. What are you seeing in the market to start the year? So, during January 2026. Can you say something about that, please?
We usually talk about Q1 at the end of Q1. But I can understand you asking the question, because it's such an important component of the story that we've been talking about in recent times. I'll make two comments on Q1 as I start the year: if you look at Europe, there's been a very strange weather pattern that's hit us, which is very unusual in our key markets at times. You've got -20 degrees temperatures. And then, of course, in India, you don't get that. So India, I think that Europe will be affected a bit by that weather position. And I think that from an India perspective, as I said earlier on, the key word was momentum. That momentum we said would build in Q4 has started to build in Q4. And we expect it to build as we go through the year because that's what we need to be able to continue with Plan A, and we're certainly on Plan A from an IPO perspective. And the team have done a good job so far. And then, we'll see how Q1 turns out. It always has a little bit of ups and downs in Q1 because of holiday patterns, etc. . So we'll see.
Appreciate it. Thanks for the comments. And then perhaps a final one from me. So you mentioned some softness ahead of Q4 in Q3 reports and the call. And now you talked about some early signs of improvements. Could you elaborate a bit on that? Is it a change of the underlying sort of macro, or is it your kind of mitigating factors that are working?
Well, that's always a very difficult one to quantify because, as it moves, it could be economic factors, or it could be the fact that what we've actually done has resonated with the consumer. What we know from history is that when we've hit this kind of patch, it's taken us one to sometimes maybe three quarters to reprofile. And then we've reprofiled and pushed through. So I think we will get some positive impacts from an economic perspective where we're seeing this softness. And I think we will get our teams doing what they've managed to do over a period of time. It's just a question of how long that takes. Q4 versus our expectations was a little bit better than we thought, Q1 let's see.
That was all for me. Thanks very much.
Thanks a lot.
The next question comes from Julia Anjali Strand from Handelsbanken. Please go ahead.
Good morning and thank you for taking my question. I have a couple and I start off with a question on India. So how much did the strike affect you? Was there a pent-up demand effect or more of a negative effect in this quarter?
Well, it was negative. Let's quantify it against what everybody remembers: this was in one state concerning the governmental pay business. Yeah. Which is a smaller percentage of our overall, every provider in that state basically didn't provide care unless it was an emergency for members of the public that were entitled to it. And this was because the local government had taken quite a long time to be able to settle all of their bills. It lasted for all of October, maybe a little bit longer, but certainly most of October. It did affect us. It did have a negative impact on us. I'm not going to quantify what that impact is. But from our perspective, we've moved through that in the quarter very successfully. I think that's the important soundbite. It won't be there in Q1 because things have returned to normal for the time being. And we fully expect, as I said earlier, that momentum is a really key word when it comes to India. And we expect that momentum to be something that we talk about after Q1.
Right. And are you able to disclose how much of the revenue in India comes from mature hospitals?
I don't think we've put that on public record. So I don't think I can, unfortunately.
Let's quantify it. As everybody remembers, this is in one state regarding the governmental pay business. Honestly. But could you instead say something about when you expect to reach mature occupancy in India, given the hospital facilities you have opened today?
Yeah. So I'll frame it slightly differently if you're looking at our occupancy journey and what will need to happen. I think we've been quite open and clear about that in many discussions that we've had in many different places. We have improved our occupancy, but it's never really been seen because as we've done that, we've opened more and more facilities and that's suppressed things. The opening of the new hospital, which has happened in soft launch, which has happened sort of the beginning of the year, is the last major investment that we have planned. And now we look to mature our occupancy rates. So it's a really key driver. It's one of the three key drivers that we talk about. The other two being doctor recruitment and the other one being the average revenue per occupied bed. So currently, we're below the 50s. Before, we've talked about being in the 50s. So it all depends on the bed mix and what's happening now. We fully expect that if our momentum picks up as it needs to, we will see occupancy start to move. If that occupancy moves, even a 10% movement up for us will be a very significant impact on our operating model. If we go further than that, then it will be an even bigger impact. So we're at the business end. We realize that, and the next couple of quarters are going to be key. So we're really looking forward to talking to you over the next couple of quarters about India.
And now we look to mature our occupancy rates. That's great. And then just one last from me, how should we think about the Fee-For-Service in Diagnostic Services? Is this an indirect effect of the German reimbursement or just the strong momentum?
No, I think that the German market will need a period of time to mature when it comes to Fee-For-Service. We'll see. Signs of Fee-For-Service growth that is both coming from the fact that it's been reformed. But also, from a lifestyle perspective, consumers are wanting different things when it comes to things like anti-aging, longevity, and all that type of thing. So there'll be a mix change as well. And some of those things are not covered under the national scheme. But Germany will take quite a while, I think, before we sit here and say we've got a Fee-For-Service market in Germany; it'll be more complementary when it comes to Fee-For-Service. And of course, if that line grows in Germany, from a margin perspective, it should be good for the model. But the other markets that we have, they are mainly led by Fee-For-Service, and we're a strong player in those markets. We have a good proposition. We have excellent service. We have a broad base of tests that we can give to people, and we have great technology that provides a platform in that network for us to take advantage of things. So I think what you're seeing is some of that benefiting us, and of course, the Synlab acquisition also benefiting us, which is driving some of the overall positivity. But it's positive. I think the key word here is that those markets are very positive for us and doing really well. And as I said before, congratulations to the team.
The next question comes from Matthias from CIB. Thank you for that. Those were all of my questions.
The next question comes from Matthias from CIB. Yes.
Hi. Good morning. Thanks for taking my questions. I have a few here as well. First one India again. So, perhaps, refreshing the topic a bit. So it must have improved quite a lot through the quarter. So what is the key contributor here? Am I correct to say the key is that you have removed the bottleneck from lack of talent to care for patients through good recruitment, or is it sort of something else that you want to add to that? Or how should we think about it? That's the first one.
Oh yeah. We said in the previous quarter that we'd focused a lot on retention and recruitment, and in that previous quarter, we also said that when you bring some of these doctors in, they're very good doctors, but it takes a period of time for customers to realize where they are, where they moved to. And it takes a period of time for our excellent marketing team to get out there. And spread the word. Et cetera. ET cetera. So recruitment is definitely a key part to it for us. And then, there are other things from an operational leverage that, from our model in India, once you increase the revenues, it starts to get really, really positive for us. And we've put a lot of technology changes into India as well, which stops some of the revenue leakage from patients. The patient flows. There's a lot of developments going on in India, but the key one, you're right, is doctor recruitment, doctor retention.
Perfect. Thanks. And then Germany, if you could provide some commentary on the.
Yeah.
Margin movements in 2025 as a whole. So we understand. Just.
I'll hold that till tomorrow. Matthias, I think there'll be something tomorrow that shows you that over a couple of year period. The only comment I'll make about it, I won't go into specifics. I'll just say that if you look at Germany over a two-year period rather than just the year of reform, that's a very positive position for us. And I think we'll share that tomorrow.
And, while we may revisit this tomorrow, could you provide high-level commentary on the anticipated CapEx-to-revenue ratio through 2028 and a rough split between the segments? And, could you, I guess we'll come back with this as well tomorrow, but could you give a high-level commentary on the anticipated CapEx to revenue ratio through 2028 and a rough split between the segments?
Fine. So I guess we continue to see opportunities to invest. So I would assume if I were you guys, that we'll keep roughly the same percentage of revenues as organic CapEx spend over the next 2 or 3 years? And I would envisage that, broadly speaking, the split would be geared towards Healthcare more than Diagnostics as well. So that's our view. And we can say for now, really.
Thanks. And one last one from me, short one. How did seasonality with Christmas and so forth impact margins in Q4 versus last year?
Yeah, you know, the holiday pattern was very frustrating for us because, you know, for those that didn't work it out, you only had to take a few days holiday and then you were off for about three weeks, I think. So there was definitely a slowdown that occurred. And that slowed down in terms of people returning post-Christmas; it was also a longer period for us. But, I think our Q4, if that hadn't happened, would have been even stronger. It's hard to say exactly the position that we would have been in. But, roughly our Q4. Q4. From our point of view, our Q4 was kind of in line with where we expected it to be, if not a little bit better in terms of some of the things we were navigating, which stands us in good stead. So, it was there. It's just one of those things. It's not one of those things that happens every single year. We just have to navigate it, move on. And in our long-term journey and our long-term objectives of what we want to do, I don't think we'll be talking about Christmas 2025 too much in our future.
Perfect. Thanks, John. And I look forward to tomorrow.
Yeah. Looking forward to seeing you. Thanks, thanks.
The next question comes from Christopher Lilienberg from Carnegie. Yeah.
Yeah. Hi.
Good morning. Two questions. First, is it possible to comment about the cost synergies from the acquisitions and how far you have come with that?
Yeah. We haven't obviously gone through a full cycle of a complete year of seeing the benefits of this. But in terms of the acquisition and post-acquisition implementation plan, we are almost complete from a lab perspective. The things that we've got left to do are things that are left to do based on the fact that the timeline would take us a little bit longer. So, things such as our purchasing coming together and getting the benefits of that; things in terms of any duplication that we had that needs to be resolved; and systems, and sending some of our more advanced tests to centralizing in Romania or Germany, those kind of things are super well progressed. From a maturity curve against ambition versus activation, the team is almost complete. Now we just need to make sure that comes through positively in our numbers as we go through the course of the next 12 months.
But is it possible to quantify the cost savings and how much more of that we should expect in 2026?
No.
No, no, I'll take that one. So no, not now. I think what we will do is in the annual report for the first time, when we report that, you'll see the split of the revenues and net income between city fit and synlab. So you'll see the numbers in there in terms of how they're flowing through into profitability. We're not showing that in this Q4 interim statement. But as John said previously as well, we've said that the sports business had a strong start and carried on. And that's fair to say that's happened. And from a lab perspective, there's still lots of opportunity there. But we had a slower start. But we're catching up now, as John said, and we're getting to the run rate where we need to be in terms of delivering on synergies and the profits that we expect, although they're both still accretive versus the underlying Medicover business is what I'd say. So in the annual report, you'll get a bit more information about it. And that's all we can say for now.
So, relative to the maturity curve for ambition versus activation, the team is almost complete. And then my second question, the margin outlook here for 2026. And the reason I'm asking is, of course, if you see the Q4 margin, it was lower than the full-year level for 2025. So how could you say anything about how we should think about 2026 margin and particularly maybe in the first half of the year here?
For the first half of the year, with the softness that we will need to navigate, we do not disclose margins by quarter or give forward projections on these things, other than our mid-term targets that we have set. But if you look at from a mid-term target perspective, we're confident over the next three years that we'll build an even stronger business model. And we've mentioned weakness, started to mention that in Q3, saying we're going to have to navigate it over a few quarters. So, that sends a slight message. And we'll see how it goes. But we're positive that we can move our margins up over a period of time. Because we've got some levers that we feel we can pull. So we are in a good position, although we don't disclose, as I say.
Okay. But if we just take the seasonal effects that were discussed here previously. So just from a seasonal perspective, Q1 versus Q4, is that stronger margin in Q1 than in Q4?
Yes, it will be. So, Q4, I think particularly given the mix in the sports business is a little bit lower in terms of how the margins flow through from a profitability perspective. So, yes, there would be better, but remember, as I've said in prior calls. We had stellar margin growth in Q1, Q2, and Q3. So we've got strong comps to anniversary as well. So yes, the seasonality levels out in terms of the movement, but strong comps to offset that. Yeah.
So, from a seasonal perspective, Q1 versus Q4, is the margin stronger in Q1 than in Q4? The next question comes from Kane Slutzkin from Deutsche Bank.
The next question comes from Kane Slutzkin from Deutsche Bank. Excuse me. Morning, guys.
Excuse me. Morning, guys. Just a quick one on Germany. Germany. You mentioned you're seeing good volume growth there despite the reform. Are you seeing competitors being squeezed out there? Is this sort of volume share gains? And then how much of the margin expansion in the diagnostics business is coming from a sort of shift towards more advanced testing and things like genetics versus more standardized testing? So, Q4, particularly given the mix in the sports business, results in slightly lower margins from a profitability perspective.
Yes. From a German market perspective, we fully discussed 'the tail' when we talked about reform all the way back in the early quarters of 2025. And that reform always, always ends up cutting the tail of some of the smaller competition. And we fully expect that to come through. So, again, when change comes like this, people want to try and trade out of it. And then eventually some of them realize that they can't. So I think there's more to come yet. And then from an advanced diagnostic perspective in our German model, our German advanced diagnostics, which includes generically our genetics business, is a strong part of our proposition. And we'll show that a bit more tomorrow. In terms of how that works and why that's important for us. And we do see growth in that particular area. And we have in 2025 invested further in that area, because we firmly believe it's a strong place for us to be, where we can grow quite strongly. So I think you'll see us talk more about that tomorrow. That will give a bit more of a flavor to it.
All right. Thanks very much.
There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.
So we got a couple of other questions. In the report. You know that you see the recovering member additions. Could you elaborate more? What is driving this recovery?
From a membership perspective. You know, we have to put everything into context. Our biggest membership business is Poland. It's much smaller in Romania. But our Polish position, as we, over, if you look back in history over the last couple of years with the extreme inflation that we were having, our focus was very much on making sure our business model was robust and that our pricing was appropriate and that we could deliver high-quality services to our customers; as a consequence of the pricing position, we didn't take a stance to say, 'let's use this to drive a high volume of membership growth.' And that's what you've seen. The inflationary position will still be relatively high, but not super high as it was, and our focus will move more towards building membership, and you will see more of that tomorrow. But also I'll mention today that some part of that will be about product development and how that product development can increase our membership. And we've done some of that already, and we see some early signs of success on some of that product development. And we see some good pipelines being developed. So, we're back into a different kind of mode as we go through 26, 27 from a membership perspective. But I'll also counter that by noting that if you look at our business mix now, we've got funded members and fee-for-service members. And you can see extreme increases in our relationships that we have from a consumer perspective, which will always also stand us in good stead. So I think we're reasonably well placed on both lines.
And what scope do you see for pricing up healthcare services for 2026, in view of the more challenging Q4 25?
We'll take our normal pricing position, which is that appropriate pricing will be put in place based upon what we see in terms of utilization and medical inflation. And if we go back the last couple of years, our pricing has been a little bit higher. You would expect it to kind of normalize to positions we had before, but we are not an organization that will discount price to get volumes. We're an organization that wants to price appropriately so that we can add value to the customer and have a nice balance between them paying us an appropriate fee and us delivering a fantastic service to them.
And the last question, would it be possible to mirror the Sports/Wellness success in Poland in other markets, or is it very particular to just Poland currently?
Today our focus is very much on Poland. It's been a fantastic addition to our portfolio. Our customers appreciate the diversity of the proposition that we can now give them in Poland. There's a slightly different pricing dynamic that comes into play because Poland has the funds from the businesses, the independent funds that can be used, the social funds, which aren't necessarily available in other countries. And we've got quite a big expansion to do in Poland. So, we've got laser focus on Poland at present.
And a final one, if you look at your last page on where you talk about where growth will come from, how do you look at the split between network expansion products?
Yeah. So I think John's.
Broadly answered that on page six of the pack. So if you look at Poland, that was 16% growth year on year in the quarter. The majority of that growth was driven by sports and wellness, which we've mentioned already. And the other material areas of growth in the quarter in healthcare were in Romania. So obviously, we've got Romanian hospitals in Healthcare Services. So that's probably it.
Just a final question.
We'll take our normal pricing position, which is that appropriate pricing will be put in place based upon what we see in terms of utilization and medical inflation. Thank you everybody. Thank you for the questions. Really good. Good session. We're really pleased with the quarter that we've had. We're really excited about the targets ahead. They're challenging, they're ambitious. They're everything that Medicover is about. So, we're very happy to take those on board and looking forward to developing the business further to achieve them. For those of you that are joining us tomorrow, we look forward to seeing you, whether you're face to face or online. And we wish you a good day. Thank you very much.



















